novo nordisk glp-1 weight loss Nordisk's oral drug didn't work on Alzheimer's as hoped, but don't call it a failure NICE recommends new treatment from

Elucidating mechanisms of action in relation to cardiorenal protection Questions remain about the mechanism of action of SGLT2 inhibitors and GLP-RAs, particularly in relation to the cardiorenal benefits observed in some diabetes CVOTs [110,111,112] (Additional file 2: Fig

They can help you understand the benefits, manage the risks, and determine the appropriate dosage for your needs

And it brings its own therapeutic properties to the table, properties that happen to address several concerns specific to weight loss therapy

These priorities are intended to help clinicians provide practical, real-world nutrition and lifestyle counseling to increase benefits, reduce risks, and improve long-term outcomes for their patients using GLP-1s